Abstract
Small studies have suggested that nucleos(t)ide analogue therapy (NAT) with reduced hepatitis B immunoglobulin (HBIG) duration may be efficacious in preventing post-liver transplantation (LT) HBV recurrence. This larger study evaluates the use of NAT with short term (< 6 mo) or no HBIG for prevention of post-LT HBV recurrence. All HBV patients undergoing LT at a university transplant center between 2002 and 2007 were identified retrospectively. Patient demographics, medication regimen, and adverse events were noted. The primary endpoint was HBV recurrence and secondary endpoints were graft and patient survival. 28 study patients were identified. Of these 28 patients, 4 (14%) received no HBIG, 6 (22%) received only inpatient HBIG, and 18 (64%) received inpatient HBIG and outpatient HBIG. 16 of the 28 patients (57%) received combination NAT and 12 patients (43%) received single NAT. At a median time of 15.5 months (range 9-24 months) post-LT, 4 of the 28 patients (14%) had recurrent HBV. Of those patients with recurrent HBV, 3 received both inpatient and outpatient HBIG and 1 received no HBIG. All cases of HBV recurrence were associated with noncompliance. NAT with short-term or no HBIG was efficacious and safe in preventing post-LT HBV. All compliant patients were HBV-free, including 9 patients who received no HBIG or only inpatient HBIG. Additional studies using NAT without HBIG appear justified.
Highlights
IntroductionSmall studies have suggested that nucleos(t)ide analogue therapy (NAT)
Small studies have suggested that nucleos(t)ide analogue therapy (NAT)with reduced hepatitis B immunoglobulin (HBIG) duration may be efficacious in preventing post-liver transplantation (LT) HBV recurrence
With reduced hepatitis B immunoglobulin (HBIG) duration may be efficacious in preventing post-liver transplantation (LT) HBV recurrence
Summary
Small studies have suggested that nucleos(t)ide analogue therapy (NAT). With reduced hepatitis B immunoglobulin (HBIG) duration may be efficacious in preventing post-liver transplantation (LT) HBV recurrence. The number of patients with hepatitis B (HBV) listed for liver transplantation (LT) in the United States has decreased by 37% since 2000, presumably due to the availability of effective oral antiviral therapy [1]. After the protective ability of long-term, high-dose hepatitis B immunoglobulin (HBIG) was recognized, HBV became an accepted indication for LT [2]. Several small studies have explored the effects of alterations to the administration route, dose, total amount, frequency, and duration of HBIG treatment while incorporating the use of oral antiviral agents with nucleos(t)ide analogue therapy (NAT) [4,5,6,7]. The transition from HBIG to NAT would provide a significant reduction in the costs, side effects, and inconveniences that are associated with HBIG, without sacrificing efficacy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have